Concepedia

Jared Lunceford

JL

Statistics

Publications

64

Citations

25.3K

H-Index

42

Active since

1999

Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)(Current)

Dana-Farber Cancer Institute

University of Chicago

Fox Chase Cancer Center

University of Washington

Jared Lunceford is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in oncology, medicine, and cancer immunotherapy.

ORCID

Publications per year

1999–2024

64

Publications

64

Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer

Edward B. Garon, Naiyer A. Rizvi, Rina Hui et al. · New England Journal of Medicine · 2015 · 6.2K citations · Full text

, , +17

IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade

Mark Ayers, Jared Lunceford, Michael Nebozhyn et al. · Journal of Clinical Investigation · 2017 · 3.9K citations · Full text

, , +17

Pan-tumor genomic biomarkers for PD-1 checkpoint blockade–based immunotherapy

Răzvan Cristescu, Robin Mogg, Mark Ayers et al. · Science · 2018 · 2.3K citations

, , +17

Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial

Tanguy Y. Seiwert, Barbara Burtness, Ranee Mehra et al. · The Lancet Oncology · 2016 · 1.7K citations

, , +13

Stratification and weighting via the propensity score in estimation of causal treatment effects: a comparative study

Jared Lunceford, Marie Davidian · Statistics in Medicine · 2004 · 1.7K citations

, , +16

1–5 of 64